Articles

Find an Article

Filter articles

Applied Filters

Showing 141 to 150 of 273 results

China v US: what can be patented in the life sciences field?

China, US09-08-2016Yu Guo

The US and China take very different approaches to the patentability of a range of inventions in the life sciences field, as Yu Guo of China Patent Agent reports.

IPR: five tips for successfully challenging Orange Book patents

US04-08-2016Mark Remus

Inter-partes reviews (IPRs) can be a powerful weapon against patents listed in the Orange Book. However, IPR practice favours a petitioner who has carefully thought about the issues and crafted the best strategy, says Mark Remus of Brinks Gilson & Lione.

Under surveillance: generic and biosimilar MAs

EU26-07-2016Ruth Franken

In order to be well prepared before a generic or biosimilar marketing authorisation is approved, drugs companies in the EU may consider monitoring pending applications, says Ruth Franken of Hogan Lovells.

Running an efficient clinical drug trial

International19-07-2016Charlie Nicholson

Everyone benefits from an efficiently run clinical drug study, including sponsors, contract research organisations, the investigator sites where patients are treated and observed, and most of all, patients, says Charlie Nicholson of Premier Research.

Varying approaches: granting SPCs in Europe

EU, France, Germany, Spain, UK14-07-2016Simon Spink and Adrian Chew

For many of the key questions relating to the grant of SPCs, there is some variance in the practice of national patent offices, even where there is guidance from the CJEU, as Simon Spink and Adrian Chew of Bristows explain.

Biologic data exclusivity in Vietnam: change is on the horizon

Vietnam14-07-2016Hien Thi Thu Vu and Huong Lan Nguyen

Several legislative changes affecting data exclusivity of biologic drugs in Vietnam are poised to come into effect, and companies operating in this sector should take note now, as Hien Thi Thu Vu and Huong Lan Nguyen of Tilleke & Gibbins explain.

From the EU to Australia: latest SPC developments

Australia, EU07-07-2016Gareth Morgan

Legislative developments surrounding supplementary protection certificates in the EU are moving fast, and may be catching on as far afield as Australia. Gareth Morgan of Olswang explains more.

Brexit and IP: business as usual, for now

EU, UK07-07-2016Claire Phipps-Jones

Following the UK’s vote to leave the EU, it is business as usual for life sciences companies working with intellectual property, at least for now, says Claire Phipps-Jones of Bristows.

‘Brexit’: time is of the essence for life sciences innovators

EU30-06-2016Laetitia Benard

The UK’s vote to leave the EU has triggered an immediate need for innovative life sciences companies to evaluate the impact on their patent strategies, argues Laetitia Benard of Allen & Overy.

Putting the boot into biologic strategies

EU, UK30-06-2016Elizabeth Ward

Is it time for healthcare regulators and patent offices to limit the strategies used by existing biologic manufacturers and allow new suppliers to reach some of the world’s most lucrative healthcare systems? Elizabeth Ward of Virtuoso Legal investigates.

Showing 141 to 150 of 273 results

LSIPR